Dermavant Sciences Annual Revenue, Number of Employees, Growth and Funding

Claim your profile


Phoenix, AZ USA
Total Funding:N/A
Lead Investor(s):NovaQuest Capital Management
Claim your profile

Industry Ranking

Growjo 10k Ranking

Estimated Revenue & Financials

  • Dermavant Sciences's estimated annual revenue is currently $8.5M per year.
  • Dermavant Sciences received $100.0M in venture funding in August 2018.
  • Dermavant Sciences's estimated revenue per employee is $144,492

Employee Data

  • Dermavant Sciences has 59 Employees.
  • Dermavant Sciences grew their employee count by 5% last year.
  • Dermavant Sciences currently has 2 job openings.

Executive Contacts

Kenneth PeistVP, Intellectual Property
Ariel JasieChief Business & Strategy Officer
Leandro SantosDirector, Topical Drug Delivery & Early DMPK
Stephen AndrewsAssociate Director, Pharmaceutical Development - Analytical CMC
Paul SeabackSVP, Technical Operations
Jen LustigExecutive Director, Human Resources
Alan ColbornDirector, Pharmaceutical Development, Analytical
Chad BerryhillExecutive Director of IT
Steve PiscitelliVice President, Clinical Pharmacology
Kara StancellVP, Investor Relations & Corporate Communications

A Passion for Science and a Commitment to Dermatology Dermavant Sciences is a specialty biopharmaceutical company developing innovative prescription therapies for dermatologic diseases. Dermavant has acquired promising compounds that address unmet therapeutic needs and has rapidly established a robust dermatology R&D pipeline. We are dedicated to realizing the full potential of biomedical research and to developing and commercializing novel first-in-class or best-in-class therapies that improve patients lives. The patient is at the heart of everything we do.



Number of Employees


Revenue (est)


Current Jobs


Employee Growth %


Total Funding







NameRevenueNumber of EmployeesEmployee GrowthTotal Funding
Sun Devil Athle...
Dermavant Scien...
Statistics & Da...

Dermavant Sciences News

09/03/2019 - Dermavant Sciences officially withdraws $100 million IPO

Dermavant Sciences, a Phase 3 biotech developing in-licensed therapies for dermatological diseases, officially withdrew its plans for an initial ...

06/05/2019 - Dermavant Sciences Announces First Patient Dosed in ...

Dermavant Sciences Announces First Patient Dosed in PSOARING, its Pivotal Phase 3 Clinical Program for Tapinarof for the Topical Treatment ...

03/27/2019 - Dermavant Sciences Announces Appointment of Cyril ...

Dermavant Sciences Announces Appointment of Cyril Allouche as Chief Financial Officer and Provides Recent Corporate Update ...

Dermavant Sciences Funding

DateAmountRoundLead InvestorsReference
2018-08-29$100.0MUndisclosedNovaQuest Capital ManagementArticle

Dermavant Sciences Executive Hires

2017-10-02Vince IppolitoPresident/cooArticle
2018-04-04David RubensteinChief Scientific OfficerArticle
2018-09-05Frank TortiExecutive ChairArticle
2018-11-16Todd ZavodnickCEOArticle
2019-01-03Philip BrownChief Medical OfficerArticle
2019-03-28Cyril AlloucheChief Financial Officer (Chief Financial Officer)Article